SCHEMBL4879015

SCHEMBL4879015

Cc1ccc(C)n1CCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
TAAR1 Q96RJ0 1/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
TSHR P16473 2/20 0.47
SLC6A3 Q01959 1/20 0.47
BRD4 O60885 1/20 0.46
LMNA P02545 2/20 0.46
RECQL P46063 1/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
GSK3A P49840 1/20 0.45
GSK3B P49841 1/20 0.45
MGLL Q99685 1/20 0.45
HRH3 Q9Y5N1 1/20 0.45
SIGMAR1 Q99720 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4878034 0.83 ALDH1A1 (0.61) MAPTSMN1; SMN2ALDH1A1KDM4ETAAR1
SCHEMBL14557080 0.78 L3MBTL1 (0.57) MAPTSMN1; SMN2ALDH1A1KDM4EMEN1
SCHEMBL19538865 0.77 KMT2A (0.59) MAPTSMN1; SMN2ALDH1A1KDM4ETAAR1
SCHEMBL9772348 0.74 PRKCI (0.45) MAPTSMN1; SMN2ALDH1A1KDM4EMEN1
SCHEMBL4771735 0.74 BCHE (0.56) MAPTSMN1; SMN2ALDH1A1KDM4ETAAR1
SCHEMBL11209828 0.73 BCHE (0.67) KDM4EMEN1KMT2ASIGMAR1
SCHEMBL29643279 0.73 BCHE (0.67) KDM4EMEN1KMT2ASIGMAR1
SCHEMBL4881337 0.72 ALDH1A1 (0.69) MAPTSMN1; SMN2ALDH1A1KDM4ETAAR1
SCHEMBL25954789 0.72 KMT2A (0.56) MAPTSMN1; SMN2ALDH1A1KDM4ETAAR1
SCHEMBL11712251 0.71 LMNA (0.67) MAPTSMN1; SMN2ALDH1A1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115536655-B Polycyclic compound for inhibiting RNA helicase DHX33 深圳开悦生命科技有限公司 2024-01-05 CN disclosed
CN-115536655-A Polycyclic compound for inhibiting RNA helicase DHX33 深圳开悦生命科技有限公司 2022-12-30 CN disclosed
CN-103483237-B Method for preparing pyrrole derivatives by catalyzing double-sulfonate ionic liquid UNIV ANHUI TECHNOLOGY 2015-04-08 CN disclosed
CN-103483237-A Method for preparing pyrrole derivatives by catalyzing double-sulfonate ionic liquid UNIV ANHUI TECHNOLOGY 2014-01-01 CN disclosed
US-20080281105-A1 Novel Quinolinium Salts and Derivatives IMMUSOL INCORPORATED (US) 2008-11-13 US disclosed
EP-1841428-A1 NOVEL QUINOLINIUM SALTS AND DERIVATIVES Immusol Incorporated (US) 2007-10-10 EP disclosed
WO-2006078754-A1 NOVEL QUINOLINIUM SALTS AND DERIVATIVES IMMUSOL INCORPORATED (US) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080281105-A1 Novel Quinolinium Salts and Derivatives NQO2, MCL1, KRAS MAPT 2491/4885SMN1; SMN2 4426/4885ALDH1A1 3206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.